Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Eton Pharmaceuticals

Nasdaq:ETON
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ETON
Nasdaq
$68M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
  • Eton Pharmaceuticals has significant price volatility in the past 3 months.
ETON Share Price and Events
7 Day Returns
-4%
NasdaqGM:ETON
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-50.9%
NasdaqGM:ETON
-2%
US Pharmaceuticals
-10%
US Market
ETON Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Eton Pharmaceuticals (ETON) -4% -18.3% -47.8% -50.9% - -
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • ETON underperformed the Pharmaceuticals industry which returned -2% over the past year.
  • ETON underperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

ETON Value

 Is Eton Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Eton Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Eton Pharmaceuticals.

NasdaqGM:ETON Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:ETON
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.63
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.629 (1 + (1- 21%) (6.85%))
0.774
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.8 * 5.44%)
6.09%

Discounted Cash Flow Calculation for NasdaqGM:ETON using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Eton Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:ETON DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.09%)
2020 -20.46 Analyst x1 -19.28
2021 -11.74 Analyst x1 -10.43
2022 9.18 Analyst x1 7.69
2023 16.22 Analyst x1 12.80
2024 22.09 Est @ 36.23% 16.44
2025 27.81 Est @ 25.88% 19.50
2026 33.00 Est @ 18.64% 21.81
2027 37.47 Est @ 13.57% 23.35
2028 41.23 Est @ 10.02% 24.21
2029 44.34 Est @ 7.54% 24.54
Present value of next 10 years cash flows $120.00
NasdaqGM:ETON DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $44.34 × (1 + 1.74%) ÷ (6.09% – 1.74%)
$1,036.46
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,036.46 ÷ (1 + 6.09%)10
$573.76
NasdaqGM:ETON Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $120.00 + $573.76
$693.76
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $693.76 / 17.88
$38.8
NasdaqGM:ETON Discount to Share Price
Calculation Result
Value per share (USD) From above. $38.80
Current discount Discount to share price of $3.83
= -1 x ($3.83 - $38.80) / $38.80
90.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Eton Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $3.83 vs Future cash flow value of $38.8
Current Discount Checks
For Eton Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Eton Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Eton Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Eton Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Eton Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ETON PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.03
NasdaqGM:ETON Share Price ** NasdaqGM (2020-04-07) in USD $3.83
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Eton Pharmaceuticals.

NasdaqGM:ETON PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ETON Share Price ÷ EPS (both in USD)

= 3.83 ÷ -1.03

-3.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eton Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Eton Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Eton Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:ETON PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
83.3%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Eton Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Eton Pharmaceuticals's assets?
Raw Data
NasdaqGM:ETON PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.59
NasdaqGM:ETON Share Price * NasdaqGM (2020-04-07) in USD $3.83
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:ETON PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ETON Share Price ÷ Book Value per Share (both in USD)

= 3.83 ÷ 0.59

6.49x

* Primary Listing of Eton Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eton Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Eton Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Eton Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ETON Future Performance

 How is Eton Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
83.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Eton Pharmaceuticals expected to grow at an attractive rate?
  • Eton Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Eton Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Eton Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ETON Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ETON Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 83.3%
NasdaqGM:ETON Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 54.9%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ETON Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ETON Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 115 17 1
2022-12-31 73 5 1
2021-12-31 43 1 3
2020-12-31 14 -12 3
2020-04-08
NasdaqGM:ETON Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 1 -18 -18
2019-09-30 1 -16 -42
2019-06-30 1 -15 -40
2019-03-31 1 -13 -41
2018-12-31 -8 -37
2018-09-30 -10 -18
2017-12-31 -7 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Eton Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Eton Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ETON Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Eton Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ETON Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.63 0.63 0.63 1.00
2022-12-31 0.21 0.21 0.21 1.00
2021-12-31 0.03 1.11 -0.65 3.00
2020-12-31 -0.60 -0.27 -0.94 3.00
2020-04-08
NasdaqGM:ETON Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.03
2019-09-30 -2.57
2019-06-30 -3.07
2019-03-31 -4.13
2018-12-31 -5.80
2018-09-30 -4.18
2017-12-31 -3.75

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Eton Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Eton Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Eton Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ETON Past Performance

  How has Eton Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Eton Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Eton Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Eton Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Eton Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Eton Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Eton Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ETON Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.96 -18.32 7.61 11.50
2019-09-30 0.50 -41.69 6.35 12.38
2019-06-30 0.50 -40.36 5.54 10.52
2019-03-31 0.50 -40.92 4.61 10.80
2018-12-31 -37.23 4.69 5.63
2018-09-30 -18.36 6.45 7.35
2017-12-31 -12.96 4.83 5.90

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Eton Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Eton Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Eton Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Eton Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Eton Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ETON Health

 How is Eton Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Eton Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Eton Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Eton Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Eton Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Eton Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:ETON Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 10.55 4.54 12.07
2019-09-30 12.35 0.00 11.78
2019-06-30 16.70 0.00 14.95
2019-03-31 19.24 0.00 19.58
2018-12-31 26.30 0.00 26.74
2018-09-30 4.75 0.00 6.60
2017-12-31 12.13 0.00 13.16
  • Eton Pharmaceuticals's level of debt (43%) compared to net worth is high (greater than 40%).
  • Unable to establish if Eton Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Eton Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Eton Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 49.9% each year.
X
Financial health checks
We assess Eton Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Eton Pharmaceuticals has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ETON Dividends

 What is Eton Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Eton Pharmaceuticals dividends.
If you bought $2,000 of Eton Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Eton Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Eton Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ETON Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ETON Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Eton Pharmaceuticals has not reported any payouts.
  • Unable to verify if Eton Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Eton Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Eton Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Eton Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Eton Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Eton Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ETON Management

 What is the CEO of Eton Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sean Brynjelsen
COMPENSATION $493,022
AGE 47
TENURE AS CEO 2.8 years
CEO Bio

Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice President of Business Development at Sagent Pharmaceuticals, Inc. since April 04, 2016. Mr. Brynjelsen served as Senior Vice President of Global Business Development at Akorn, Inc. since June 2014. Mr. Brynjelsen served as Vice President of New Business Development at Akorn, Inc. until June 2014. Previously, Mr. Brynjelsen served as Vice President of New Business Development and R&D of Akorn Inc. Mr. Brynjelsen has extensive experience in pharmaceutical transactions, strategic planning and product licensing/development, which makes him a great addition to executive leadership team. Mr. Brynjelsen has over 20 years of transactional experience in the pharmaceutical industry with companies including Akorn, Hospira and Baxter. Mr. Brynjelsen’s background included pharmaceutical development, due diligence, project management and strategic planning. Mr. Brynjelsen joined Akorn in April 2007 as Director of New Business Development. In December, 2007 he took on the additional responsibility as head of Contract Manufacturing. Prior to joining Akorn, Mr. Brynjelsen held progressively responsible positions within R & D and Program Management at Hospira International and Baxter Healthcare Corporation. Mr. Brynjelsen holds a BS in Biochemistry and MS in Chemistry from the University of Illinois and an MBA from the University of Notre Dame.

CEO Compensation
  • Sean's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Sean's remuneration is about average for companies of similar size in United States of America.
Management Team

Sean Brynjelsen

TITLE
President
COMPENSATION
$493K
AGE
47
TENURE
2.8 yrs

W. Troutman

TITLE
CFO, Treasurer & Secretary
COMPENSATION
$297K
AGE
64
TENURE
2.8 yrs

Scott Grossenbach

TITLE
Vice President of Sales & Marketing

Bharathi Devarakonda

TITLE
Senior Vice President of Regulatory Affairs & Product Development

David Krempa

TITLE
Vice President of Business Development
Board of Directors Tenure

Average tenure and age of the Eton Pharmaceuticals board of directors in years:

2.8
Average Tenure
61
Average Age
  • The average tenure for the Eton Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Norbert Riedel

TITLE
Chairman
COMPENSATION
$125K
AGE
61
TENURE
1.6 yrs

Sean Brynjelsen

TITLE
President
COMPENSATION
$493K
AGE
47
TENURE
2.8 yrs

Paul Maier

TITLE
Independent Director
COMPENSATION
$125K
AGE
71
TENURE
2.6 yrs

Chuck Casamento

TITLE
Independent Director
COMPENSATION
$125K
AGE
74
TENURE
2.8 yrs

Mark Baum

TITLE
Director
COMPENSATION
$125K
AGE
46
TENURE
3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
13. Aug 19 Buy Sean Brynjelsen Individual 13. Aug 19 13. Aug 19 5,000 $6.15 $30,750
12. Aug 19 Buy Charles Casamento Individual 09. Aug 19 09. Aug 19 3,500 $6.11 $21,370
22. May 19 Buy Sean Brynjelsen Individual 20. May 19 21. May 19 10,000 $7.96 $79,326
X
Management checks
We assess Eton Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Eton Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ETON News

Simply Wall St News

What Kind Of Shareholder Appears On The Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shareholder Register?

With a market capitalization of US$123m, Eton Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. … General Public Ownership The general public, who are mostly retail investors, collectively hold 53% of Eton Pharmaceuticals shares. … Public Company Ownership Public companies currently own 20% of ETON stock.

Simply Wall St -

Who Has Been Buying Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Eton Pharmaceuticals, Inc. … For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' Check out our latest analysis for Eton Pharmaceuticals Eton Pharmaceuticals Insider Transactions Over The Last Year Director Mark Baum made the biggest insider purchase in the last 12 months. … In the last twelve months Eton Pharmaceuticals insiders were buying shares, but not selling.

Simply Wall St -

ETON Company Info

Description

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. The company offers Biorphen, a phenylephrine hydrochloride injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. It also develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-203, which is injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101 and ET-104, which are oral liquid product candidates for neurological indications; DS-300 and DS-100, which are injectable product candidates; and ET-105, a lamotrigine for oral suspension. Eton Pharmaceuticals, Inc. was founded in 2017 and is based in Deer Park, Illinois.

Details
Name: Eton Pharmaceuticals, Inc.
ETON
Exchange: NasdaqGM
Founded: 2017
$68,489,921
17,882,486
Website: http://www.etonpharma.com
Address: Eton Pharmaceuticals, Inc.
21925 West Field Parkway,
Suite 235,
Deer Park,
Illinois, 60010-7208,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ETON Common Stock Nasdaq Global Market US USD 13. Nov 2018
Number of employees
Current staff
Staff numbers
17
Eton Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 15:03
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/03/05
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.